Article Figures & Data
Figures
- Fig. 1.
The reduction from baseline in tumor volume at week 12 as measured by calipers, ultrasound, and mammography in patients administered either (a) 1 mg/day or (b) 10 mg/day of anastrozole.
- Fig. 2.
Relationship between pathological and calliper (left), mammography (middle), and ultrasound (right) tumor volumes (mm3) for all of the patients.
Tables
- Table 1
Patient demographics and baseline tumor characteristics
Anastrozole 1 mg/day (n = 12) 10 mg/day (n = 12) Age (yr)a 74.1 ± 8.7 68.8 ± 8.9 Weight (kg)a 69.6 ± 9.6 77.5 ± 14.2 Height (cm)a 156.3 ± 12.2 157.8 ± 11.7 Tumor stageb T2 11 (91.7) 10 (83.3) T3 0 (0) 2 (16.7) T4B 1 (8.3) 0 (0) Lymph node metastases 2 (16.7) 1 (8.3) Tumor volume assessment (cm3) Caliper Median 23.7 27.3 Maximum 42.4 161.0 Minimum 12.4 10.9 Ultrasound Median 4.8 4.9 Maximum 9.9 14.3 Minimum 2.4 1.4 Mammography Median 7.3 8.4 Maximum 25.5 47.7 Minimum 1.4 0.7 -
a Mean ± SD.
-
b No. of patients, with percentage in parens.
-
- Table 2
Tumor volume after 12 weeks of anastrozole treatment
Assessment method Anastrozole 1 mg/day 10 mg/day Tumor volume (cm3) % Reduction from baseline Tumor volume (cm3) % Reduction from baseline Caliper n 12 12 11 11 Median 2.0 89.3 0.1 99.6 Maximum 7.9 100.0 50.1 100.0 Minimum 0.0 74.0 0.0 −8.8 Ultrasound n 12 12 11 11 Median 0.9 80.5 1.4 69.6 Maximum 2.5 95.7 5.1 97.6 Minimum 0.3 6.3 0.1 −16.8 Mammography n 12 12 11 11 Median 1.8 73.6 5.6 69.3 Maximum 5.6 98.8 22.5 100.0 Minimum 0.1 37.0 0.0 8.1 - Table 3
Tumor shrinkage in response to treatment with anastrozole treatment for 12 weeks
Change from baseline after 12 weeks of treatment Caliper Ultrasound Mammogram Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) 100% decrease (i.e., lesions disappeared) 2 3 0 0 0 2 >75 to <100% decrease 9 5 8 4 5 3 50–75% decrease 1 2 3 3 3 1 <50% decrease to 25% increase 0 1 1 4 4 5 >25% increase 0 0 0 0 0 0 - Table 4
Difference between assessment and surgical specimen tumor volumes for all of the patients who had a measurable 12-week assessment (measured at 12 weeks), treated with anastrozole, irrespective of dose
Caliper Ultrasound Mammography n 23 23 23 Median −0.24 −0.12 −1.33 Q1a −4.88 −0.67 −2.80 Q3 0.44 0.79 −0.35 Maximum 6.15 4.39 5.69 Minimum −42.60 −1.89 −14.91 -
a Q1, lower quartile (25% of data); Q3, upper quartile (75% of data).
-
- Table 5
Bidimensional measurements
Change from baseline in product of bidimensional measurements Clinical Ultrasound Mammogram Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) Anastrozole, 1 mg/day (n = 12) Anastrozole, 10 mg/day (n = 11) 100% decrease 2 3 0 0 0 2 >50% decrease 10 6 9 7 8 4 <50% decrease to 25% increase 0 2 3 4 4 5 - Table 6
TNM clinical stage before and after treatment and pathological nodal status
Patient no. TNMa stage before treatment TNM stage after treatment Nodal status (pathology assessment) 1 T2N0M0 T1N0M0 0 /5 2 T2N0M0 T1N0M0 1 /4 3 T2N0M0 T1N0M0 4 /5 4 T3N0M0 T2N0M0 2 /5 5 T2N1M0 T1N0M0 1 /7 6 T2N0M0 T1N0M0 0 /5 9 T2N0M0 T2N1M0 0 /4 11 T2N0M0 T1N0M0 2 /3 12 T2N0M0 T1N0M0 0 /4 13 T2N0M0 T1N0M0 0 /2 14 T2N0M0 T1N0M0 2 /7 15 T2N0M0 T2N0M0 0 /5 16 T2N0M0 T1N0M0 0 /5 17 T2N0M0 T1N0M0 0 /4 18 T2N0M0 T1N0M0 0 /7 19 T2N0M0 T2N0M0 1 /18b 20 T3N1M0 T2N1M0 17 /22b 21 T2N0M0 T0N0M0 3 /6 22 T2N0M0 T1N0M0 0 /4 23 T2N0M0 T0N0M0 0 /5 24 T2N0M0 T2N0M0 0 /4 25 T4bN1M0c T2N1M0 3 /4 26 T2N0M0 T0N0M0 0 /3 -
a TNM, tumor, node, metastasis.
-
b Patients underwent mastectomy plus axillary clearance (all of the other patients had wide local excision and axillary node sampling).
-
c Peau d’orange.
-
Volume 6, Issue 6
